An observational study in FGF23-related Hypophosphataemic Rickets and Osteomalacia, sponsored by Kyowa Kirin Korea Co., Ltd.. Recruiting at 13 sites in South Korea. Open to participants aged 1 Day and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Kyowa Kirin Korea Co., Ltd. (part of Kyowa Kirin Co., Ltd.) · Observational
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings
34 studies on the registry are indexed under Osteomalacia; 3 are open to participants now.
This study's planned enrollment of 100 is above the median of 65 across 14 observational studies indexed under Osteomalacia.
Browse Osteomalacia studies →Kyowa Kirin Korea Co., Ltd. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
FGF23-related hypophosphataemic rickets and osteomalacia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FGF23-related hypophosphataemic rickets and osteomalacia
safety (Special situation, adverse event, symptom, or disease occuring during treatment with a drug)
Investigators have to record all events (i.e., all AEs and special situations) in CRFs including undesirable medical findings obtained during the medical examination as well as spontaneous reports from subjects. All AEs occurring for at least 4 weeks after the last dose of CRYSVITA® should be included in this study
Time frame: 4 weeks after follow up
Serum Phosphorus Concentration
1\) Change from baseline over time in Serum Phosphorus Concentration (mg/dL), up to Week 24
Time frame: 24 weeks
1,25-Dihydroxyvitamin D
2\) Change from baseline over time in 1,25-Dihydroxyvitamin D, up to Week 24
Time frame: 24 weeks
Plan to share: Undecided — Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.